Cybin Enters US$30-Million Common Share Purchase Agreement
On May 30, 2023, Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, entered into a common share purchase agreement (the “Agreement”) with Lincoln Park Capital Fund, LLC, an institutional investor.
Subject to the terms and conditions of the Agreement, the Company has the right to sell up to US$30 million of the Company’s common shares over a 36-month period at prices that are based on the market price at the time of each sale. The sale of common shares under the Agreement will be made pursuant to and qualified by way of a prospectus supplement dated May 30, 2023 (the “Supplement”), to the Company’s short form base shelf prospectus dated July 5, 2021. The Supplement was also filed with the United States Securities and Exchange Commission, as part of a registration statement on Form F-10, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
Aird & Berlis acted for Cybin with a team that included Sherri Altshuler, Danny Kharazmi, Amy Marcen-Gaudaur, Sean Green, Meredith McCann (Capital Markets) and Barbara Worndl (Tax).